Search

A recent study conducted at the University of Virginia focused on the effectiveness of stereotactic radiosurgery (SRS) in treating supratentorial hemangioblastomas (HBs) in patients with Von Hippel-Lindau Disease. The study included 13 patients with 30 HBs, comparing outcomes between Von Hippel-Lindau (VHL) and sporadic cases. Results showed that SRS demonstrated promising results in the clinical course of supratentorial HBs, suggesting it as an effective alternative to surgical resection in selected cases. The research has been peer-reviewed and provides valuable insights into the treatment of this rare condition. [Extracted from the article]

Researchers at Mayo Clinic in Rochester, Minnesota have conducted a study on the use of the drug belzutifan in the treatment of hemangioblastomas, a type of tumor. Belzutifan is the first FDA-approved treatment for tumors related to von Hippel-Lindau (VHL) disease, which can cause hemangioblastomas. The study found that belzutifan may delay or eliminate the need for surgery or radiation therapy by inhibiting a specific protein involved in the growth of these tumors. While further research is needed, the study suggests that belzutifan could be a promising treatment option for hemangioblastomas. [Extracted from the article]